Revenue segments as reported by the company.

Cannabis revenue

Distribution revenue

Beverage alcohol revenue

Wellness revenue

Adult-use

Canada - Medical

International - Medical

Bulk

Hemp

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Impairment of Assets

Litigation settlement

Transaction costs

Change in fair value of contingent consideration

Restructuring costs

Other than temporary change in fair value of convertible notes receivable

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Tilray Brands

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America. The firm is focused on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It operates through the following segments: Cannabis and Hemp. The Cannabis segment consists of adult-use, medical and bulk sales of cannabis under regulated licenses and sold to retail, wholesale, pharmacy, government, and direct to patient. The Hemp segment consists of hemp seed, hemp foods, and broad spectrum hemp extract containing CBD, which are sold in an unlicensed operation and sold to retail, wholesale and direct to consumers. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Earnings data Q1 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Tilray Brands reports record revenue and optimistic outlook for 2025

Tilray Brands achieved remarkable financial performance in Q4 2024, driven by strategic acquisitions and a focus on innovation. Despite challenges like price compression, the company remains optimistic about future growth opportunities. Tilray's commitment to quality products and innovation positions it well for continued success in the market.

Tilray Brands reports record Q1 revenue growth and global expansion

Tilray Brands delivered a robust performance in Q1 2025, showcasing strong revenue growth, margin improvement, and strategic expansion across its diversified product portfolio.
While facing challenges in a competitive landscape and evolving regulatory environment, Tilray's financial strength, international growth initiatives, and focus on innovation position it well for future success.
By capitalizing on opportunities in wellness products, expanding into new beverage categories, and leveraging strategic partnerships, Tilray is poised for continued growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. The Cannabis Business segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution Business segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage Alcohol Business segment refers to the production, marketing, and sale of beverages. The Wellness Business segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

NANAIMO, British Columbia--(BUSINESS WIRE)--Tilray Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY), a global pioneer in cannabis production, research, cultivation and distribution, announced today it will report results for the second quarter ended June 30, 2020 on Monday, August 10, 2020 after market close.

Tilray to Report Second Quarter 2020 Financial Results on August 10, 2020

Aphria

Cronos Group

Aurora Cannabis stock dipped after the company said it will cut staff in Europe by one quarter and scale back other operations.

Marijuana Stocks Fall Amid Industry's Latest International Pullback

Both of these pot stocks are struggling this year, but which one is more likely to turn things around?

Better Cannabis Stock to Buy: Tilray or Charlotte's Web?

Aurora Cannabis

Canopy Growth

Curaleaf Holdings, Inc.

GW Pharmaceuticals

HEXO Corp

Innovative Industrial Properties

As the coronavirus breakout was just beginning to be seen as a major threat to our health and to the economy back in March, it wasn’t clear what the implications might be to the cannabis industry, which was already struggling with a capital crunch that had intensified during the vaping crisis in.

Three Reasons To Be Bullish On Cannabis Stocks

The company's solution to high production costs is to scale up operations -- even while making cuts elsewhere.

Tilray Is Still Trying to Be a Growth Stock. Is It a Brilliant Strategy or a Misguided Move?

Amazon

Tesla

Dominion Energy

Tesla, Amazon, Dominion Energy, Sea Ltd and Tilray were our top stock trades for Tuesday. So, let's take a closer look at the charts now.

5 Top Stock Trades for Tuesday: TSLA, AMZN, TLRY, SE, D

The best defense during a market downturn is usually a good offense. Here are two high-growing cannabis companies that are likely to continue their momentum.

Which of These 2 Ultra-Growth Stocks Is Best?

Amyris

Cara Therapeutics

These marijuana stocks on the Nasdaq are top for value, growth, and performance for July 2020.

Top Marijuana Stocks on the NASDAQ for July 2020

GLJ Research founder Gordon Johnson joined Benzinga’s PreMarket Prep show on June 23.

Analyst Explains Why He's Bearish On Tilray And Aurora Cannabis, Recommends MSOs

Even after a robust rally in the overall market, Tilray stock still can't harness lasting momentum. I will continue to avoid TLRY stock.

Continue Avoiding Tilray Stock as Charts, Fundamentals Lag

Green Thumb Industries Inc.

OrganiGram Holdings Inc.

Trulieve Cannabis Corp.

Amid recession and social unrest, the cannabis industry sees its moment.

Why more states could legalize cannabis in 2021

Although Tilray posted some impressive revenue gains, the bottom line is that the company is still losing money, making TLRY stock riskier than you might think.
The post Don’t Let Positive Revenue Confuse Your Outlook on Tilray appeared first on InvestorPlace.

Don’t Let Positive Revenue Confuse Your Outlook on Tilray

Tilray isn't out of the race by any means

Does Tilray Have the Right Stuff to Become a Global Leader?

Pot stock valuations have plummeted, and these CEOs could pay the price for this underperformance.

3 Cannabis Stock CEOs Who May Lose Their Jobs

Many cannabis investors may want to pick Aurora or Cronos instead of TLRY stock, but Tilray could continue growing going forward.
The post Why Tilray Is Still a Very Risky Cannabis Stock appeared first on InvestorPlace.

Why Tilray Is Still a Very Risky Cannabis Stock

Tilray, Inc.'s (TLRY) Management Presents at Oppenheimer 20th Annual Consumer Growth and E-Commerce Conference 2020 - Transcript

Although Tilray stock has looked interesting since hitting a sharp low in March, the viability of its long-term trajectory is a huge question mark.
The post Only the Most Daring Need Apply for Tilray appeared first on InvestorPlace.

Only the Most Daring Need Apply for Tilray

These three pot stocks are soaring -- unfortunately their rallies lack substance.

Despite Doubling, These Cannabis Stocks Are Bad News

Tilray's earnings are showing signs of modest improvement. However, the balance sheet underlying TLRY stock is not strong enough to support heavy losses for too long.

Cannabis Is Recovering, But Tilray Still Faces Stiff Challenges

There are good marijuana stocks out there, but these Canadian cannabis companies have serious red flags.

3 Pot Stocks to Stay Miles Away From

Cannabis stocks in general stumbled in the latter half of last year. Wall Street expects profits, and none of these companies is anywhere near profitability.

Short Sellers Hike Their Bets in Cannabis Stocks

TLRY stock has had an impressive run since mid-March even though Tilray keeps posting net losses and struggles with profit margins.
The post Expect Some Profit-Taking After Tilray’s Bull Run appeared first on InvestorPlace.

Expect Some Profit-Taking After Tilray’s Bull Run

The cannabis company delivered better-than-expected results and got a further boost from a big state moving towards legalization.

Why Tilray Stock Surged 22.4% in May

TLRY stock is down over 97% in under two years, and there's no stopping the free fall as the company struggles on multiple fronts.
The post Only a Miracle Can Save Tilray Stock Now appeared first on InvestorPlace.

Only a Miracle Can Save Tilray Stock Now

Tilray has promise but near-term volatility should make investors cautious about TLRY stock.
The post Approach Volatile Cannabis Producer Tilray Stock With Caution appeared first on InvestorPlace.

News for Tilray Brands Stock (TLRY)